Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA12 | O43570 | 4/20 | 0.64 |
| ▸ | CA2 | P00918 | 4/20 | 0.64 |
| ▸ | CA9 | Q16790 | 3/20 | 0.64 |
| ▸ | SIRT2 | Q8IXJ6 | 1/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.48 |
| ▸ | MAPT | P10636 | 4/20 | 0.48 |
| ▸ | POLB | P06746 | 2/20 | 0.48 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.48 |
| ▸ | MPI | P34949 | 1/20 | 0.48 |
| ▸ | RECQL | P46063 | 1/20 | 0.48 |
| ▸ | HPGD | P15428 | 2/20 | 0.45 |
| ▸ | RAB9A | P51151 | 2/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.45 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.44 |
| ▸ | GAA | P10253 | 2/20 | 0.44 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.44 |
| ▸ | USP2 | O75604 | 1/20 | 0.44 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.44 |
| ▸ | HTT | P42858 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1946250 | 0.85 | CA12 (0.75) | CA12CA2CA9SIRT2ALDH1A1 | |
| SCHEMBL1946252 | 0.85 | CA12 (0.75) | CA12CA2CA9SIRT2ALDH1A1 | |
| SCHEMBL9273920 | 0.84 | CA12 (0.68) | CA12CA2CA9SIRT2ALDH1A1 | |
| SCHEMBL9273922 | 0.84 | CA12 (0.68) | CA12CA2CA9SIRT2ALDH1A1 | |
| SCHEMBL11413806 | 0.81 | CA12 (0.64) | CA12CA2CA9SIRT2ALDH1A1 | |
| SCHEMBL11413807 | 0.81 | CA12 (0.64) | CA12CA2CA9SIRT2ALDH1A1 | |
| SCHEMBL710477 | 0.79 | CA12 (1.00) | CA12CA2CA9SIRT2ALDH1A1 | |
| SCHEMBL803089 | 0.79 | CA12 (1.00) | CA12CA2CA9SIRT2ALDH1A1 | |
| SCHEMBL30361105 | 0.79 | CA12 (1.00) | CA12CA2CA9SIRT2ALDH1A1 | |
| SCHEMBL29359256 | 0.79 | CA12 (1.00) | CA12CA2CA9SIRT2ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230226185-A1 | METHODS AND COMPOSITIONS FOR INDUCING FERROPTOSIS IN VIVO | Kojin Therapeutics, Inc. | 2023-07-20 | — | — | US | disclosed |
| US-11541116-B1 | Methods and compositions for inducing ferroptosis in vivo | Kojin Therapeutics, Inc. (US) | 2023-01-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230226185-A1 | METHODS AND COMPOSITIONS FOR INDUCING FERROPTOSIS IN VIVO | AIFM2, GPX4, SLC40A1 | CA12 1567/4885CA2 1512/4885CA9 3247/4885 |
| US-11541116-B1 | Methods and compositions for inducing ferroptosis in vivo | AIFM2, GPX4, SLC40A1 | CA12 1567/4885CA2 1512/4885CA9 3247/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.